Abstract
Prospective real-world data studies integrated into routine clinical workflows can capture multimodal longitudinal data in patients (pts) with cancer treated in community settings. One modality is circulating tumor DNA (ctDNA), a minimally invasive, readily available test for genomic profiling, investigating resistance or monitoring disease. Using the PCG study platform to prospectively collect and link real-world clinico-genomic, imaging and outcomes data, this exploratory analysis assessed the association of longitudinal ctDNA measurement and clinical response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
